Heterocyclic compounds are described that are lysophosphatidic acid receptorligands that are useful in the treatment of lysophosphatidic acid receptor-dependentdiseases and conditions, including but not limited to diseases involvingfibrosis, such asfibrosis of the heart, kidney, liver and lung,and scleroderma； inflammatorydiseasessuch as diabetic nephropathy and nonalcoholic steatohepatitis (NASH)； oculardiseasessuch as diseases involving retinal degeneration； nerve diseases such aspruritus andpain.
